Utility decrements associated with side effects in schizophrenia

References

• Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317-33
   PubMed Web of Science ®Google Scholar
• Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009;35:937-48
   PubMed Web of Science ®Google Scholar
• Clark SL, Adkins DE, van den Oord EJ. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res 2011;132:114-20
   PubMed Web of Science ®Google Scholar
• Sevy S, Nathanson K, Schechter C, et al. Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia. Schizophr Bull 2001;27:643-51
   Google Scholar
• Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-59
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43
   PubMed Web of Science ®Google Scholar
• Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010;81:617-22
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013;64:393-406
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-9
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(1 Suppl):83-96
   Google Scholar
• Fetter JC. Weight gain and quality of life among patients taking antipsychotics. Psychiatr Serv 2003;54:1041
   Google Scholar
• Medeiros-Ferreira L, Obiols JE, Navarro-Pastor JB, et al. Metabolic syndrome and health-related quality of life in patients with schizophrenia. Actas Esp Psiquiatr 2013;41:17-26
   Google Scholar
• Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(2 Suppl):3-7
   Google Scholar
• Gao K, Mackle M, Cazorla P, et al. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat 2013;9:1145-57
   PubMed Web of Science ®Google Scholar
• Miller DD. Sedation with antipsychotics: Manage, don't accept adverse ‘calming' effect. Curr Psychiatry 2007;6:8.
   Google Scholar
• Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-7
   PubMed Web of Science ®Google Scholar
• Meesters PD, Comijs HC, de HL, et al. Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. Schizophr Res 2013;147:275-80
   PubMed Web of Science ®Google Scholar
• Sigaudo M, Crivelli B, Castagna F, et al. Quality of life in stable schizophrenia: the relative contributions of disorganization and cognitive dysfunction. Schizophr Res 2014;153:196-203
   Google Scholar
• Staring AB, Mulder CL, Duivenvoorden HJ, et al. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. Schizophr Res 2009;113:27-33
   Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl 2009;(438):22-8
   Google Scholar
• Dolan P. The measurement of health-related quality of life for use in resource allocation decisions in health care. Handbook of Health Economics. In: Culyer AJ, Newhouse J, eds. North Holland: Elsevier; 2014. pp 1723-60
   Google Scholar
• Bebbington PE, Angermeyer M, Azorin JM, et al. The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol 2005;40:707-17
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects (revised October 7, 2000). HIV Clin Trials 2001;2:92-5
   Google Scholar
• Assemblée Nationale et Sénat. Data files and individual liberties (amended by the act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data). Journal officiel de la République Française 2004;(Act No 78-17 of 6 January 1978 on Data Processing)
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994
   Google Scholar
• Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001;7:41-7
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;(7):59-67
   Google Scholar
• Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 2002;41:417-22
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Morss SE, Lenert LA, Faustman WO. The side effects of antipsychotic drugs and patients’ quality of life: patient education and preference assessment with computers and multimedia. Proc Annu Symp Comput Appl Med Care 1993:17-21
   PubMedGoogle Scholar
• Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment, 1997
   Google Scholar
• Cummins C. SAKS. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee report. Birmingham: Development and Evaluation Service. Department of Public Health and Epidemiology, University of Birmingham, 1998
   Google Scholar
• Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care 2000;38:1011-21
   PubMed Web of Science ®Google Scholar
• Lee TT, Ziegler JK, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000;34:201-10
   PubMed Web of Science ®Google Scholar
• Oh P, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
   PubMed Web of Science ®Google Scholar
• Adrianzen C, Arango-Davila C, Araujo DM, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol 2010;25:439-47
   PubMed Web of Science ®Google Scholar
• NHS; National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008. Ref Type: Report. ISBN: 1-84629-741-9
   Google Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). 24-4-2003. Ref Type: Report
   Google Scholar
• Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272:619-26
   PubMed Web of Science ®Google Scholar
• Boyer L, Baumstarck K, Boucekine M, et al. Measuring quality of life in patients with schizophrenia:an overview. Expert Rev Pharmacoecon Outcomes Res 2013;13:343-9
   PubMed Web of Science ®Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics 2000;17:273-86
   PubMed Web of Science ®Google Scholar
• Baumstarck K, Boyer L, Boucekine M, et al. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr Res 2013;147:58-67
   PubMed Web of Science ®Google Scholar
• Siddique R, Markowitz J, Engelhart L. Impact of atypical antipsychotic drug sedation on quality of life. Atlanta, GA: American Psychiatric Assocociation, 2005 . Abstract no NR765; plus poster
   Google Scholar
• McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009;12:27-31
   PubMed Web of Science ®Google Scholar
• Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics 2010;28:1109-21
   PubMed Web of Science ®Google Scholar
• Millier A, Perthame E, Aballea S, Toumi M. Comparison of the SF-6D and the EQ-5D in patient with schizophrenia. ISPOR 14th Annual European Congress, Madrid, Spain, 2011
   Google Scholar
• Byerly MJ, Nakonezny PA, Fisher R, et al. An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 2006;81:311-16
   PubMed Web of Science ®Google Scholar
• Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007;22:238-43
   PubMed Web of Science ®Google Scholar
• Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003;29:289-96
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001;7:41-7
   PubMedGoogle Scholar